Skip to content

April 2026

Addiction

What April 2026's 6 new studies found, synthesized from the papers below. All Addiction research →

The synthesis

Synthesized from 2 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Addiction, substance use disorder, dependence, alcohol use disorder, opioid use disorder, then ranked by relevance.

Research on addiction in April 2026 is limited and preliminary. A narrative review suggests ibogaine shows promise for substance use disorders but raises serious safety concerns, particularly cardiotoxicity. A preclinical study found that psilocybin did not restore social deficits caused by methamphetamine-fentanyl withdrawal in rats. Overall, the evidence is sparse, mostly preclinical or review-based, and does not support a clear conclusion about the efficacy of psychedelics for addiction.

Confidence in the evidence

Insufficient
  • Only two studies directly address addiction: one narrative review (no original data) and one preclinical rat study.
  • The narrative review on ibogaine highlights safety concerns and calls for more RCTs, indicating low confidence in current evidence.
  • The preclinical study found psilocybin ineffective for social deficits in a polysubstance withdrawal model, but this is animal data.
  • Two other studies are off-topic (autism, meditation scales) and one is a publisher placeholder with no data.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

The Efficacy and Safety of Ibogaine Treatment for Substance Use Disorders - A Narrative Review 2026
Supports

Ibogaine shows promising potential for reducing withdrawal symptoms and cravings in substance use disorders, but serious safety concerns (cardiotoxicity, QT prolongation) exist.

narrative review

Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations. 2026
No effect

Psilocybin pretreatment did not restore social preference deficits caused by methamphetamine-fentanyl polysubstance withdrawal in rats.

preclinical (animal study)

Points of agreement

  • Both studies focus on psychedelics (ibogaine, psilocybin) in the context of substance use disorders or withdrawal.
  • Both highlight the need for more rigorous research (RCTs, further studies).

Conflicts

  • No direct conflicts; the studies address different substances (ibogaine vs. psilocybin) and different outcomes (withdrawal/cravings vs. social behavior).

Gaps

  • No human clinical trials on psilocybin for addiction published in April 2026.
  • No large-scale RCTs on ibogaine for addiction; safety data is limited.
  • Durability of any effects, optimal dosing, and long-term outcomes are unstudied.
  • Preclinical findings may not translate to humans.
Browse these studies in the library